Money A2Z Web Search

Search results

1. Results From The WOW.Com Content Network

2. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   Amgen. non-small cell lung cancer with KRAS G12C mutation. Avapritinib. Blueprint Medicines Corp. granted for two indications: mast cell leukemia and advanced systemic mastocytosis. Belumosudil. Kadmon Pharmaceuticals. chronic graft-versus-host disease. Pembrolizumab.

3. US FDA approves Lilly's Alzheimer's drug - AOL

   www.aol.com/news/us-fda-approves-lillys...

   July 2, 2024 at 1:55 PM. The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for ...

4. List of withdrawn drugs - Wikipedia

   en.wikipedia.org/wiki/List_of_withdrawn_drugs

   Alpidem (Ananxyl) 1995. Worldwide. Not approved in the US, withdrawn in France in 1994 [4] and the rest of the market in 1995 because of rare but serious hepatotoxicity. [3] [5] Alosetron (Lotronex) 2000. US. Serious gastrointestinal adverse events; ischemic colitis; severe constipation. [2]

5. Anakinra - Wikipedia

   en.wikipedia.org/wiki/Anakinra

   Anakinra. Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease. [3] It is a slightly modified recombinant version of the human interleukin 1 receptor antagonist protein. [3]

6. Naxitamab - Wikipedia

   en.wikipedia.org/wiki/Naxitamab

   Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication.It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.

7. Aducanumab - Wikipedia

   en.wikipedia.org/wiki/Aducanumab

   Formula. C6472H10028N1740O2014S46. Molar mass. 145 912.34 g·mol −1. Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's ...